Patents by Inventor Els Vercammen

Els Vercammen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
    Publication number: 20060128624
    Abstract: The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 15, 2006
    Inventors: Wing Cheung, David Gibson, Christine Cote, Els Vercammen
  • Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
    Publication number: 20060100150
    Abstract: The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.
    Type: Application
    Filed: December 15, 2005
    Publication date: May 11, 2006
    Inventors: Wing Cheung, David Gibson, Christine Cote, Els Vercammen
  • Pharmaceutical compositions of erythropoietin
    Publication number: 20040248797
    Abstract: The present invention provides aqueous pharmaceutical formulations of erytropoietin that are free of human serum blood products, stabilized with a quantity of an amino acid and a sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivative. The present invention also provides aqueous stable, preserved pharmaceutical formulations of erythropoietin that contain an antimicrobial quantity of cresol and a quantity of an amino acid.
    Type: Application
    Filed: February 10, 2004
    Publication date: December 9, 2004
    Applicant: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Wing K. Cheung, Jaya Natarajan, Marilyn Sanders, Els Vercammen, Selima Begum, Basant Sharma
  • Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
    Publication number: 20040176297
    Abstract: The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.
    Type: Application
    Filed: March 24, 2004
    Publication date: September 9, 2004
    Inventors: Wing Cheung, David Gibson, Christine Cote, Els Vercammen
  • Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
    Publication number: 20040157778
    Abstract: The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.
    Type: Application
    Filed: March 24, 2004
    Publication date: August 12, 2004
    Inventors: Wing Cheung, David Gibson, Christine Cote, Els Vercammen
  • Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
    Patent number: 6747002
    Abstract: The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: June 8, 2004
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Wing Cheung, David Gibson, Christine Cote, Els Vercammen
  • Pharmaceutical compositions of erythropoietin
    Patent number: 6696056
    Abstract: The present invention provides aqueous pharmaceutical formulations of erythropoietin that are free of human serum blood products, stabilized with a quantity of an amino acid and a sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivative. The present invention also provides aqueous stable, preserved pharmaceutical formulations of erythropoietin that contain an antimicrobial quantity of cresol and a quantity of an amino acid.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: February 24, 2004
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Wing K. Cheung, Jaya Natarajan, Marilyn Sanders, Els Vercammen, Selima Begum, Basant Sharma
  • Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
    Publication number: 20030198691
    Abstract: The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.
    Type: Application
    Filed: May 10, 2000
    Publication date: October 23, 2003
    Inventors: Wing Cheung, David Gibson, Christine Cote, Els Vercammen